Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: A review

International Journal of Infectious Diseases

Volumn 10, Issue 2, 2006, Pages 136-147

  Fogarty, Charles M ^a   Buchanan, Patricia ^b   Aubier, Michel ^c   Baz, Malik ^d   Van Rensburg, Dirkie ^e   Rangaraju, Manickam ^f   Nusrat, Roomi ^f  

^a Spartanburg Pharmaceutical Research ^*  (United States)

^b River Road Medical Group   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ABM Research Institute   (United States)

^e Medpark Centre   (South Africa)

^f SANOFI   (France)

Author keywords

Bacteriologic efficacy; Clinical efficacy; Ketolide; Streptococcus pneumoniae; Telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFUROXIME AXETIL; CLARITHROMYCIN; ERYTHROMYCIN; PENICILLIN G; TELITHROMYCIN; TROXACITABINE;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER FUNCTION TEST; PENICILLIN RESISTANCE; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 32844475741     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.01.003     Document Type: Article

References (63)

1. P. Oh, and A. McIvor The pharmacoeconomics of respiratory tract infections Clin Pulm Med 3 1996 323 328
2. M.S. Niederman, J.S. McCombs, A.N. Unger, A. Kumar, and R. Popovian The cost of treating community-acquired pneumonia Clin Ther 20 1998 820 837
3. M.S. Niederman, J.S. McCombs, A.N. Unger, A. Kumar, and R. Popovian Treatment cost of acute exacerbations of chronic bronchitis Clin Ther 21 1999 576 591
4. N.F. Ray, J.N. Baraniuk, and M. Thamer Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders J Allergy Clin Immunol 103 1999 408 414
5. P. Ball Therapy for pneumococcal infection at the millennium: doubts and certainties Am J Med 107 Suppl. 1A 1999 77S 85S
6. J.G. Bartlett, S.F. Dowell, L.A. Mandell, T.M. File Jr., D.M. Musher, and M.J. Fine Practice guidelines for the management of community-acquired pneumonia in adults Clin Infect Dis 31 2000 347 382
7. J. Garau The clinical impact of macrolide resistance in pneumococcal respiratory infections Int J Antimicrob Agents 18 Suppl. 1 2001 33 38
8. J.G. Bartlett IDCP guidelines: management of upper respiratory tract infections Infect Dis Clin Pract 6 1997 212 220
9. A. Örtqvist Treatment of community-acquired lower respiratory tract infections in adults Eur Respir J 20 Suppl. 36 2002 40s 53s
10. P. Ball Epidemiology and treatment of chronic bronchitis and its exacerbations Chest 108 Suppl. 1995 43S 52S
11. L.R. Willett, J.L. Carson, and J.W. William Jr. Current diagnosis and management of sinusitis J Gen Intern Med 9 1994 38 45
12. J.G. Bartlett, and L.M. Mundy Community-acquired pneumonia N Engl J Med 333 1995 1618 1624
13. W.R. Bishai Issues in the management of bacterial sinusitis Otolaryngol Head Neck Surg 127 6 Suppl. 2002 S3 S9
14. D. Felmingham, R.R. Reinert, Y. Hirakata, and A. Rodloff Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin J Antimicrob Chemother 50 Suppl. S1 2002 25 37
15. D. Felmingham, C. Feldman, and W. Hryniewicz Surveillance of resistance in bacteria causing community-acquired respiratory tract infections Clin Microbiol Infect 8 Suppl. 2 2002 12 42
16. A.L. Barry, P.C. Fuchs, and S.D. Brown In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae Antimicrob Agents Chemother 42 1998 2138 2140
17. G.A. Pankuch, D.B. Hoellman, G. Lin, S. Bajaksouzian, M.R. Jacobs, and P.C. Appelbaum Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay Antimicrob Agents Chemother 42 1998 3032 3034
18. P.M. Roblin, and M.R. Hammerschlag In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae Antimicrob Agents Chemother 42 1998 515 516
19. T. Schülin, C.B. Wennersten, M.J. Ferraro, R.C. Moellering Jr., and G.M. Eliopoulos Susceptibilities of Legionella spp. to newer antimicrobials in vitro Antimicrob Agents Chemother 42 1998 1520 1523
20. Fogarty C, Patel TC, Galbraith H, et al. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae [Abstract 857]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, December 16-19, 2001. Washington, DC: American Society for Microbiology; 2001. p. 449.
21. M. Aubier, P.M. Aldons, and A. Leak Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis Respir Med 96 2002 862 871
22. L. Hagberg, A. Torres, D.J. van Rensburg, B. Leroy, M. Rangaraju, and E. Ruuth Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for the treatment of community-acquired pneumonia Infection 30 2002 378 386
23. S.R. Norrby, W.J. Rabie, and P. Bacart Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis Scand J Infect Dis 33 2002 883 890
24. K. Roos, C. Brunswig-Pitschner, and R. Kostrica Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis Chemotherapy 48 2002 100 108
25. Tellier G, Isakov T, Patel M, et al. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs. clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L-373]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, September 27-30, 2002. Washington, DC: American Society for Microbiology; 2002. p. 346.
26. D.J. van Rensburg, P.A. Matthews, and B. Leroy Efficacy and safety of telithromycin in community acquired pneumonia Curr Opin Med Res 18 2002 397 400
27. P. Buchanan, T. Stephens, and B. Leroy A comparison of the efficacy of telithromycin vs. cefuroxime axetil in the treatment of acute maxillary sinusitis Am J Rhinol 17 2003 369 377
28. C. Carbon, S. Moola, I. Velancsics, B. Leroy, M. Rangaraju, and P. Decosta Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia Clin Microbiol Infect 9 2003 691 703
29. Fogarty C, de Wet R, Nusrat R. Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis [Abstract 2230]. In: Abstracts of the 13th Annual Congress of the European Respiratory Society, Vienna, Austria, September 27-October 1, 2003. Eur Respir J 2003; 22(Suppl. 45):351s.
30. Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs. amoxicillin/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis. Ear Nose Throat J 2003;82:576-80, 582-4, 586 passim.
31. J. Pullman, J. Champlin, and P.S. Vrooman Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults Int J Clin Pract 57 2003 377 384
32. J. Quinn, G.E. Ruoff, and P.S. Ziter Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study Clin Ther 25 2003 422 443
33. M.J. Zervos, A.M. Heyder, and B. Leroy Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis J Int Med Res 31 2003 157 169
34. L.M. Dunbar, J. Hassman, and G. Tellier Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults Clin Ther 26 2004 48 62
35. Fogarty C, van Rensburg D, De Salvo C, Rangaraju M, Nusrat R. Efficacy of a 7-day course of oral telithromycin 800 mg once daily in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4 2004. Prague, Czech Republic.
36. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved standard 7th Edition M2-A7 2000 National Committee for Clinical Laboratory Standards Wayne, PA
37. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Disk Susceptibility Tests; 11th informational M100-S11 2001 National Committee for Clinical Laboratory Standards Wayne, PA
38. British Thoracic Society Guidelines for the management of community-acquired pneumonia in adults Thorax 56 Suppl. 4 2001 1 64
39. M.S. Niederman, L.A. Mandell, and A.A. Anzueto Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730 1754
40. S.G. Adams, and A. Anzueto Antibiotic therapy in acute exacerbations of chronic bronchitis Semin Respir Infect 15 2000 234 247
41. R.E. Hillberg The role of infection in acute exacerbations of chronic obstructive airways disease Am J Manag Care 6 8 Suppl. 2000 S427 S436
42. M.S. Niederman Antibiotic therapy of exacerbations of chronic bronchitis Semin Respir Infect 15 2000 59 70
43. Sinus and Allergy Health Partnership Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol Head Neck Surg 123 2000 5 31
44. C.M. Fogarty, S. Kohno, P. Buchanan, M. Aubier, and M. Baz Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J Antimicrob Chemother 51 2003 947 955
45. L. Hagberg, C. Carbon, D.J. van Rensburg, C. Fogarty, L. Dunbar, and J. Pullman Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis Respir Med 97 2003 625 633
46. Low DE, Felmingham D, Rangaraju M, Nusrat R. Potent activity of telithromycin in the treatment of key respiratory pathogens associated with community-acquired upper and lower respiratory tract infections [Abstract P1128]. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003. Clin Microbiol Infect 2003; 9(Suppl. 1):267.
47. C. Carbon A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults Infection 31 2003 308 317
48. J. Garau Clinical failures: the tip of the iceberg? Respir Med 95 Suppl. A 2001 S5 S11
49. J.R. Lonks, J. Garau, and L. Gomez Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin Infect Dis 35 2002 556 564
50. M.A. Kelley, D.J. Weber, P. Gilligan, and M.S. Cohen Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin Clin Infect Dis 31 2000 1008 1011
51. M.A. Jackson, V.F. Burry, L.C. Olson, S.E. Duthrie, and G.L. Kearns Breakthrough sepsis in macrolide-resistant pneumococcal infection Pediatr Infect Dis J 15 1996 1049 1051
52. Garau J, Lonks JR, Gomez L, et al. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae [Abstract 7.09]. In: Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26-28, 2000. Georgia, PA: ICMAS Inc.; 2000. p. 65.
53. G.W. Waterer, R.G. Wunderink, and C.B. Jones Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy Chest 118 2000 1839 1840
54. D.M. Musher, M.E. Dowell, and V.D. Shortridge Emergence of macrolide resistance during treatment of pneumococcal pneumonia N Engl J Med 346 2002 630 631
55. D. Van Kerkhoven, W.E. Peetermans, L. Verbist, and J. Verhaegen Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams J Antimicrob Chemother 51 2003 691 696
56. C. Fogarty, R. Goldschmidt, and K. Bush Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin Clin Infect Dis 31 2000 613 615
57. M.B. Kays, M.F. Wack, D.W. Smith, and G.A. Denys Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation Diagn Microbiol Infect Dis 43 2002 163 165
58. T.B. Hyde, K. Gay, and D.S. Stephens Macrolide resistance among invasive Streptococcus pneumoniae isolates JAMA 286 2001 1857 1862
59. S. Douthwaite Structure-activity relationships of ketolides vs. macrolides Clin Microbiol Infect 7 Suppl. 3 2001 7 11
60. O.A. Khair, J.M. Andrews, D. Honeybourne, G. Jevons, F. Vacheron, and R. Wise Lung concentrations of telithromycin after oral dosing J Antimicrob Chemother 47 2001 837 840
61. C. Muller-Serieys, P. Soler, and C. Cantalloube Bronchopulmonary disposition of the ketolide antimicrobial, telithromycin (HMR 3647) Antimicrob Agents Chemother 45 2001 3104 3108
62. M.J. Fine, M.A. Smith, and C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis JAMA 275 1996 134 141
63. T.J. Marrie Pneumococcal pneumonia: epidemiology and clinical features Semin Respir Infect 14 1999 227 236